Active Ingredient(s): Velaglucerase Alfa
FDA Approved: * February 26, 2010
Pharm Company: * SHIRE
Category: Enzymes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Vpriv Overview

Velaglucerase alfa, sold under the brand name Vpriv and manufactured by Shire plc, is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase indicated as a long-term enzyme replacement therapy for those suffering of Gaucher disease Type 1. It has an identical amino acid sequence to the naturally occurring enzyme.[1] It was approved for use by the U.S. Food and Drug Administration (FDA) on February 26, 2010.[2]...

Read more Vpriv Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Velaglucerase_alfa

Recent Vpriv Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Velaglucerase Alfa
  • Injection: 200units, 400 units/vial, 400units
  • Powder: 200 units/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Vpriv: (1 result)

Sorted by National Drug Code
  • 54092-701 Vpriv 2.5 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Shire Us Manufacturing Inc.

Other drugs which contain Velaglucerase Alfa or a similar ingredient: (1 result)